Profound Medical Corp

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The firm's platforms offer clinicians and patients incision-free alternatives to current standards of care, which could include traditional surgery or radiation therapy. Its products include TULSA-PRO and Sonalleve. The company was founded in 2008 and is headquartered in Mississauga, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Profound Medical Corp reports revenue growth and eyes expansion opportunities

Profound Medical Corp's Q4 2022 performance reflects revenue growth driven by recurring revenue and progress in key trials and applications.
While facing financial challenges and capacity constraints, the company's strengths lie in the growing adoption of TULSA-PRO and AI software innovations.
Opportunities for growth include pending trial results, AI software value proposition, and expansion plans in key states, positioning the company for future success.

Profound Medical Corp reports revenue growth and expansion opportunities

Profound Medical Corp shows promising revenue growth and recurring revenue increase in Q1 2023, driven by the success of TulsaPro and Sonalleve platforms. While facing challenges in managing expenses and reducing backlog, the company is focused on expanding installations and preparing for reimbursement to drive future growth.

Profound Medical Corp reports revenue growth amidst widened net loss

Profound Medical Corp reported strong revenue growth in Q2 2023, driven by their innovative treatment technologies.
While facing challenges with a widened net loss, the company's focus on operational efficiency and market expansion presents growth opportunities.
Future prospects include expanding the install base, improving margins, and leveraging AI technology to drive profitability and market reach.

Profound Medical Corp reports revenue growth amidst profitability challenges

Profound Medical Corp's Q3 2023 performance showed revenue growth and strong cash reserves, but challenges persist in managing expenses and achieving profitability.
The company's strengths include recurring revenue growth, strategic partnerships, and innovative developments in AI applications for medical procedures.
Addressing operational challenges and seizing opportunities in market expansion and technology advancements will be crucial for future success.

Profound Medical Corp reports robust revenue growth and strategic focus

Profound Medical Corp's Q4 2023 performance showed strong revenue growth and strategic focus on TULSA's market adoption and innovation.
While facing challenges with patient reimbursement and payment models, the company aims to capitalize on opportunities for expansion and increased utilization.
By emphasizing customer retention, technology advancement, and market awareness, Profound Medical Corp positions itself for sustained growth and success in the prostate cancer treatment market.

Profound Medical Corp reports Q1 growth, eyes TULSA technology opportunities

Profound Medical Corp's Q1 2024 performance reflects a mix of revenue growth and operational improvements.
The company's focus on innovative TULSA technology and strategic collaborations positions it for future success.
While facing financial challenges and high operating expenses, Profound's growth outlook remains positive.
Navigating reimbursement rates and optimizing revenue streams are key priorities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Profound Medical Corp. engages in developing, manufacturing, and marketing of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. Its platforms offer clinicians and patients incision-free alternatives to current standards of care, which could include traditional surgery or radiation therapy. Its products include TULSA-PRO and Sonalleve. The company was founded in 2008 and is headquartered in Mississauga, Canada.

TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 13,437,920 common shares, representing 63.64% of the common shares outstanding, were represented in person and by proxy at the Meeting.

Profound Medical Annual and Special Meeting of Shareholders Voting Results

Profound Medical Corp. (NASDAQ:PROF ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO and Chairman Rashed Dewan - CFO Conference Call Participants Rahul Sarugaser - Raymond James Michael Sarcone - Jefferies Ben Haynor - Alliance Global Partners Joshua Jennings - TD Cowen Frank Takkinen - Lake Street Capital Markets Brian Gagnon - Gagnon Securities Operator Good day and thank you for standing by. Welcome to the Profound Medical First Quarter 2023 Financial Results Conference Call.

Profound Medical Corp. (PROF) Q1 2023 Earnings Call Transcript

– Presentations reinforce the safety, efficacy and durability of the TULSA procedure, further supporting its potential as a mainstream, whole gland or focal treatment for prostate disease –

TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting

Profound Medical (PROF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Profound Medical (PROF) Moves 9.4% Higher: Will This Strength Last?

TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2023 financial results after market close on Wednesday, May 10, 2023.

Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow

TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 26, 2023 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre.

Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

The heavy selling pressure might have exhausted for Profound Medical (PROF) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging -15.27% in 4 Weeks, Here's Why the Trend Might Reverse for Profound Medical (PROF)

Profound Medical Corp. (NASDAQ:PROF ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Arun Menawat – Chief Executive Officer and Chairman Rashed Dewan – Chief Financial Officer Conference Call Participants Michael Sarcone – Jefferies Rahul Sarugaser – Raymond James Ben Haynor – Alliance Frank Takkinen – Lake Street Brian Gagnon – Gagnon Securities Scott McAuley – Paradigm Capital Operator Good day and thank you for standing by. Welcome to the Profound Medical Fourth Quarter and Full Year 2022 Financial Results Conference Call.

Profound Medical Corp. (PROF) Q4 2022 Earnings Call Transcript

Company confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSA Company confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSA

Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results

TORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company's business at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 9:10 a.m. Eastern Time.

Profound Medical to Present at the 43rd Annual Cowen Health Care Conference

TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2022 financial results after market close on Tuesday, March 7, 2023.

Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow

Investors have repriced Profound Medical to the upside, with a strong rally that commenced in December. The momentum has continued into the new year, and we've re-entered with a small ticket.

Profound Medical: Upsides Leading Into FY22 Earnings, Revise To Buy

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains?

Profound Medical (PROF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Recent Price Trend in Profound Medical (PROF) is Your Friend, Here's Why

TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company's business at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:20 p.m. GMT.

Profound Medical to Present at the 2022 Jefferies London Healthcare Conference

Invesco DWA Industrials Momentum Portfolio

Profound Medical Corp. (NASDAQ:PROF ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Michael Sarcone - Jefferies Rahul Sarugaser - Raymond James Brian Gagnon - Gagnon Securities Operator Good day, and thank you for standing by. Welcome to the Profound Medical Incorporated Third Quarter 2022 Conference Call.

Profound Medical Corp. (PROF) Q3 2022 Earnings Call Transcript

TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2022 financial results after market close on Thursday, November 3, 2022.

Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow

TORONTO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that updated results from the TACT (TULSA-PRO® Ablation Clinical Trial) pivotal study were presented for the first time this past weekend, on Saturday, September 24, 2022, by Laurence Klotz, M.D., FRCSC, CM, Professor of Surgery, University of Toronto and Sunnybrook Chair of Prostate Cancer Research, at the FOCAL 2022 Conference held in Los Angeles, CA.

Four Year Follow-Up Data from Profound Medical's TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer

TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in September.

Profound Medical to Participate in September Investor Conferences

TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today provided a U.S. reimbursement update for Transurethral Ultrasound Ablation (“TULSA”), performed with its TULSA-PRO® system.

Profound Medical Provides TULSA-PRO® Reimbursement Update

Profound Medical Corp. (NASDAQ:PROF ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Zach Weiner - Jefferies Rahul Sarugaser - Raymond James Operator Welcome to the Profound Medical Second Quarter 2022 Financial Results Conference Call. My name is Darryl, and I'll be your operator for today's call.

Profound Medical Corp. (PROF) CEO Dr. Arun Menawat on Q2 2022 Results - Earnings Call Transcript

Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 6.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Reports Q2 Loss, Tops Revenue Estimates

Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Profound Medical (PROF) Q2 Earnings Expected to Decline

TORONTO, July 14, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2022 financial results after market close on Thursday, August 4, 2022.

Profound Medical to Release Second Quarter 2022 Financial Results on August 4 – Conference Call to Follow

Profound Medical Corp. is at an inflection point in its growth engine, set to recognize first meaningful revenue from its TULSA-PRO segment in FY22. Nevertheless, investors have shied away from top-line growth and are rewarding bottom-line fundamentals with a premium instead.

News for Profound Medical Corp Stock (PROF)